Slide 1: Alembic Pharmaceuticals Limited Investor Presentation Q3FY25
Alembic Pharmaceuticals Limited Investor Presentation Q3FY25 Feb 03, 2025
Slide 2: Safe Harbour Statement
Safe Harbour Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diff
Slide 3: Quarterly Snapshot
Quarterly Snapshot INR Bn Key Highlights : 4% YoY Revenue R&D India Branded Business : India Branded Business 16.93 3% QoQ 7% of Sales recorded 3% growth with topline of INR 6.14 billion for Q3 FY25. US Generics : Growth of 10% on YoY basis is driven by ramp up of the key launches and market share g
Slide 4: Revenue Snapshot
Revenue Snapshot INR Bn Business Q3 FY25 Q3 FY24 Y-o-Y Q2 FY25 Q-o-Q 9M FY25 9M FY24 Y-o-Y Formulations India 6.14 5.96 3% 6.09 1% 17.95 16.97 6% US 5.21 4.74 10% 4.67 11% 14.49 13.08 11% Ex-US 2.99 2.72 10% 2.98 1% 8.68 7.90 10% API 2.59 2.89 -10% 2.74 -5% 7.91 9.16 -14% Total Revenue 16.93 16.31 4
Slide 5: Diversified Therapy Presence
Diversified Therapy Presence Revenue – Q3 FY25 Revenue – 9M FY25 INR Bn INR Bn Growth: 3% CAGR: 12% 5.96 6.14 17.95 16.97 15.73 0.96 1.17 14.78 Animal Health 1.81 11.39 2.03 Acute Specialty 2.98 3.16 Q3FY24 Q3FY25 9M FY21 9M FY22 9M FY23 9M FY24 9M FY25 Sales Mix – Q3 FY25 Anti Infective ➢ India Bus
Slide 6: Branded Business – Rx driven rankings
Branded Business – Rx driven rankings Top Brands with Rank and Market Share Driving overall Prescription Business *Figures in Mn Rank MS% Rank MS% BRANDS Q3 Q3 BRANDS Q3 Q3 128 0.23 46 FY 25* FY 25 FY 25* FY 25 AZITHRAL 1 30.8 CLOFF 3 13.5 MAT Dec 24 ALTHROCIN 1 87.1 SHARKOFERROL 3 6.6 MAT Dec 23 CR
Slide 7: High focus therapies
High focus therapies ➢ Gynecology, Anti Diabetic, Ophthalmology and Dermatology have shown good growth. Q3 FY25 Growth Comparison Therapy APL Market* Gynaecology 7% 5% Anti Diabetic 15% 17% Ophthalmology 12% 13% Dermatology 13% 15% *Above market growth are based on respective Molecule group Source:
Slide 8: New Launches
New Launches New launches continue to do well along with promising future launches across key segments. Q3 FY25 Therapy Molecule Brands Launch INR Mn Dydrogesterone / Dydrogesterone SR ISOFIT/ISOFIT SR 2022 183 Gynecology Iron Ferric RICHAR-FCM/TUFEHART 2023 36 Gastrointestinal Raft Mkt ULGERAFT/EVA
Slide 9: Animal Health Business
Animal Health Business Revenue – Q3 FY25 Revenue – 9M FY25 Growth 22% CAGR 25% INR Mn 3330 2740 2190 Q3FY24 1795 Q3FY25 1,170 1388 960 Q3FY24 Q3FY25 FY21 FY22 FY23 FY24 FY25 Sales Mix – Q3 FY25 ➢ Operating in Livestock and Poultry and Companion animal market. Antibiotic 38% ➢ Leaders in Hematinic an
Slide 10: Technology transforming business
Technology transforming business ➢Deployment of Ipads for MR interaction with the Healthcare Medical Professional’s (HMP’s) - Upgrading our scope to communicate medico-marketing content to the HMP for our brands along with an increased time spend during calls. ➢Upgraded to SalesForce platform for In
Slide 11: US Business
US Business Revenue- Q3 FY25 Revenue – Last 5 years 5.21 INR Bn INR Bn 4.74 Growth 10% 21.63 19.76 17.30 16.66 15.72 Q3FY24 Q3FY25 FY20 FY21 FY22 FY23 FY24 Approved ANDAs Injectable 16 ➢Well-established US front end with strong customer base. Inhalation 2 Derma 30 ➢2 products launched in Q3FY25. Cum
Slide 12: Ex-US Business
Ex-US Business Revenue – Q3 FY25 Revenue – Last 5 years INR Bn INR Bn Growth 10% 2.99 2.72 CAGR: 21% 10.52 8.52 7.79 7.75 Q3FY24 Q3FY25 ➢Growth of 10% driven by high demand across the markets. 4.97 ➢Ex-US driven by partnership in following key markets - Europe, Canada, Australia, Brazil and South Af
Slide 13: API Business
API Business Revenue – Q3 FY25 Revenue – Last 5 years INR Bn INR Bn 2.89 De-Growth (-10%) 2.59 CAGR: 15% 12.46 11.66 9.55 9.39 Q3FY24 Q3FY25 7.08 ➢Decline of 10% on YoY basis, on account of the pricing headwinds and low off–take from few selected customers. ➢1 US DMF filed in Q3 FY25. 135 Cumulative
Slide 14: R&D Dosage form wise ANDA approval and Launch R&D Capabilities
R&D Dosage form wise ANDA approval and Launch R&D Capabilities Q3FY25 Dosage Forms Formulation : Vadodara and Hyderabad Approval* Launch OSD 5 2 API : Vadodara and Hyderabad Injectable - Gen 0 0 Bio Centre : Vadodara Injectable - Onco 0 0 Ophthalmology 2 0 Dermatology 0 0 Other 0 0 Total 7 2 *Includ
Slide 15: Yearly Financials
Yearly Financials Revenue INR Bn EBIDTA Net Profit INR Bn INR Bn 16.31 11.78 62.29 10.53 # 9.61 56.53 7.79 # 6.65 # 6.16 53.93 4.97 # 53.06 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 EBIDTA margin % Capex INR Bn ROCE % 41 * 30 6.87 20 # 4.67 25*# 15 4.12 14 # 3.45 14*# 15 FY21 FY22
Slide 16: Enhancing ESG compliance
Sustainability Enhancing ESG compliance Commissioned 12 MW Solar park at Bhatpur, Gujarat Targets: Developed 82 Nos. of recharge well and planted 20,000 Trees so far 19% Reduction in Indirect Energy Consumption 28% Reduction in Water Consumption(KL/MT) ➢ Net-Zero by 2040 16% Reduction (YoY) in Total
Slide 17: Strategic Roadmap
Strategic Roadmap Business Initiatives in FY24 Plan for FY25 • Increased focus on the animal health space with therapy leading products. • Improve depth in the current strength with new launches • Deployment of Ipads for MR interaction with the planned in FY 25 & launches done in FY 24. The India Bu
Slide 18: Company Overview
Company Overview
Slide 19: Company at a Glance
Company at a Glance Mission Prescribers in India Improve healthcare with innovation, commitment and trust 2,33,000 Team size Field Force 14,500 + 5,200 + Brands Manufacturing facilities 9 201 ANDA filings Net Zero 263 (Dec 31, 2024) 2040 R&D Centres Products in US 2 159
Slide 20: Value Proposition
Value Proposition Developing Supplying APIs Ranks 20th in the specialty drug to 60+ countries Indian formulations pipeline for India globally market Exploring Consistent and Established a opportunities in High Dividend presence in Chile Injectables Payout & UAE Strengthening presence Expanding in Ca
Slide 21: The Journey
The Journey 1907 2007 2008 2009 2010 2012 2006 Acquired Dabur’s FDA approved Pharmaceutical Established by FDA approved FDA approved APIIndian Cardiology, facility FDA approved Multiple divisions to business demerged Formed a JV, Amin Family GI and Gynecology Formulation address chronic API facility
Slide 22: Robust Infrastructure
Robust Infrastructure Last USFDA Location Dosage Form Audit International Generics F1 – Panelav General Oral Solids July’24* Oncology Oral Solids Mar’24* F2 – Panelav Oncology Injectables Oct’24 F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Mar’23* F4 – Jarod General Oral S
Slide 23: Thank you
For further queries, please contact: Mr. Ajay Desai ajay.desai@alembic.co.in 022-6695 3681 Thank you Investor Relations Advisors : Adfactors PR Pvt. Ltd. Snighter Albuquerque snighter.a@adfactorspr.com Darshan Mankad darshan.mankad@adfactorspr.com